SAN DIEGO, CA -- (Marketwired) -- 05/06/13 -- La Jolla Pharmaceutical Company (OTCBB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics targeting technology/galectins/">galectin proteins, announced today that it has treated the last patient in the Phase 1 (Part A) portion of the Phase 1/2 clinical trial of technology/gcs-100-technology/">GCS-100 in patients with chronic kidney disease ("CKD"). A total of 29 patients with Stage 3b and 4 CKD were enrolled and treated. La Jolla expects to release data from this portion of the clinical trial later this month.
"We are very pleased with the quick progress made enrolling the Phase 1 portion of the trial and believe this underscores the significant unmet medical need of CKD patients. We are evaluating the data and hope to release the results shortly," said George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla.
The primary objectives of the study include evaluating the safety of a single dose (Part A) and repeat doses (Part B) of GCS-100. Secondary study objectives include evaluating galectin-3 serum levels, renal function, and other markers of disease activity in CKD. The study is open to patients at least 18 years of age with moderately severe to severe renal impairment. While not currently anticipated, the study design may be amended from time-to-time to comply with requests from the FDA, the governing Institutional Review Board, study investigators, or at the discretion of the Company.
About Chronic Kidney Disease
Chronic kidney disease currently affects 14% of Americans or approximately 49 million people. The United States Renal Data System, 2012 Annual Data Report, states that in 2010, costs for CKD reached $41 billion for Medicare alone. Overall per person per year costs for CKD were estimated at $22,323 for Medicare patients of age 65 and older and $13,395 for patients of age 50-64. Patients with CKD may progress to end-stage renal disease ("ESRD"). According to the National Institute of Diabetes and Digestive and Kidney Diseases as of 2008, there were 547,982 individuals in the US under treatment for ESRD and 88,630 deaths per year from ESRD.
GCS-100 is a complex polysaccharide that has the ability to bind to and block the effects of technology/galectins/">galectin-3. Galectin-3 is a soluble protein, over-expression of which has been implicated in a number of human diseases including cancer and technology/galectins/role-in-chronic-organ-failure/">chronic organ failure. The unique ability of GCS-100 to bind and sequester galectin-3 makes it an ideal candidate to prevent and treat diseases in which galectin-3 plays an important role.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit http://www.ljpc.com.
Forward Looking Statement Safe Harbor
This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC's web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100 and LJPC-501, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 and LJPC-501 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264
Chester S. Zygmont, III
Director of Finance
La Jolla Pharmaceutical Company
Phone: (858) 207-4262
Most Popular Stories
- 5 Notable Hispanic Technology Executives
- Top Hispanic Tech Companies Push for the Top
- Tesla's Alt-Energy Future Aims for Massive Lithium-Ion Battery Production
- Rand Paul Tops Presidential Straw Poll at Conservative PAC Conference
- China Urges Malaysia Flight Emergency Response
- New Chat App, Yik Yak, Causes Problems for Students
- Russia, Crimea Discuss Referendum
- Gas Prices May Jump from Calif. Emissions Law
- Visa, MasterCard Team Up to Focus on Payment Security
- Obama Meets with Ukraine Prime Minister Wednesday